Elevated serum levels of IL-2R, IL-1RA and CXCL9 are associated with a poor prognosis in follicular lymphoma
Menée initialement à partir d'échantillons sériques prélevés sur 209 patients atteints d'un lymphome folliculaire récemment diagnostiqué et sur 400 témoins, puis validée sur une cohorte complémentaire de 183 patients, cette étude identifie trois cytokines (IL-2R, IL-1RA et CXCL9) dont les niveaux, mesurés avant une chimiothérapie, sont associés à un pronostic défavorable
Serum cytokines and chemokines may reflect tumor biology and host response in follicular lymphoma (FL). To determine whether addition of these biological factors may further refine prognostication, 30 cytokines and chemokines were measured by multiplex ELISA in pre-treatment serum specimens from newly diagnosed FL patients (n=209) prospectively enrolled on the University of Iowa/Mayo Clinic SPORE Molecular Epidemiology Resource (MER) between 2002-2008 and from 400 matched controls. Cytokine levels were correlated with clinical outcome in patients who were observed or received single agent rituximab, or those who received chemotherapy. Correlations with outcome in chemotherapy treated patients were further examined in a separate cohort of 183 SWOG patients and all patients were then included in a meta-analysis. Six cytokines were associated with outcome in the MER after adjusting for the FLIPI. In patients who were observed or treated with rituximab alone, increased serum IL-12 and IL-1RA (p=0.005 and 0.02) were associated with a shorter EFS. In patients receiving chemotherapy, HGF, IL-8, IL-1RA and CXCL9 (p=0.015, 0.048, 0.004 and 0.0005) predicted a shorter EFS. When the MER chemotherapy treated patients and SWOG patients were combined in a meta-analysis, IL-2R, IL-1RA and CXCL9 (p= 0.013, 0.042 and 0.0012) were associated with a poor EFS.
Blood , résumé, 2013